SN-38

For research use only. Not for use in humans.

目录号:S4908 别名: NK012

SN-38 Chemical Structure

CAS No. 86639-52-3

SN-38 (NK012)是CPT-11的一种活性代谢物,抑制DNA topoisomerase I,DNA合成,并造成频繁的DNA单链断裂。SN-38 可诱导自噬。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 794.43 现货
RMB 742.35 现货
RMB 3013.44 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的SN-38发表文献40篇:

产品安全说明书

ADC Cytotoxin抑制剂选择性比较

生物活性

产品描述 SN-38 (NK012)是CPT-11的一种活性代谢物,抑制DNA topoisomerase I,DNA合成,并造成频繁的DNA单链断裂。SN-38 可诱导自噬。
靶点
Topo I [1]
(Cell-free assay)
体外研究

SN-38是伊立替康盐酸盐(CPT-11)的生物活性代谢物。SN-38引起DNA拓扑异构酶I的抑制最强,其次是CPT,然后是CPT-11。 CPT-11剂量依赖性地转移宽松的DNA在切口的DNA的方向上的位置,但SN-38和CPT对宽松的DNA的位置没有影响。SN-38的剂量依赖性和时间依赖性地抑制DNA的合成。 SN-38的各自的IC50值,在DNA合成是0.077微米。SN-38的细胞RNA合成的抑制作用小于对DNA合成和它不抑制蛋白质的合成。 SN-38对P388细胞造成频繁的DNA单链断裂。[1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
human DU145 prostate cell line MVXQdo9tcW[ncnH0bY9vKGG|c3H5 NYjKbnVZSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDEWVE1PSCycn;zeIF1\SClZXzsJIxqdmVuIFnDOVA:OTNibl2= NHntelg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMES5PFIyPid-MUC0PVgzOTZ:L3G+
human MCF-7 breast cell line NGK4TZdRem:uaX\ldoF1cW:wIHHzd4F6 MUfBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRj23JIJz\WG|dDDj[YxtKGyrbnWsJGlEPTB;MD6zO{DPxE1? MnW4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB2OUiyNVYoRjFyNEm4NlE3RC:jPh?=
human SKOV-3 ovarian cell line NHuxWoJRem:uaX\ldoF1cW:wIHHzd4F6 MWHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFONT2[tN{BwfmG{aXHuJINmdGxibHnu[UwhUUN3ME2wMlczKM7:TR?= MoP0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB2OUiyNVYoRjFyNEm4NlE3RC:jPh?=
human breast cancer cell line (SK-BR-3) M4e0eWN6fG:2b4jpZ:Kh[XO|YYm= MXHJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDidoVie3RiY3HuZ4VzKGOnbHygcIlv\SBqU1utRnIuOyluIFnDOVA:PCCwTR?= NGXDXVM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN|Q2Pjl:L3G+
human lung cancer cell line (H128) MoTmR5l1d3SxeHnjxsBie3OjeR?= MkDvTY4hXmm2cn:gZ5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gcJVv\yClYX7j[ZIh[2WubDDsbY5mKCiKMUK4LUwhUUN3ME22JI5O NWm3fZhkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGzN|Q2PjlpPkGxN|M1PTZ7PD;hQi=>
human stomach cancer cell line (MKN45) MULDfZRwfG:6aXRCpIF{e2G7 NVy3S|FJUW5iVnn0do8h[3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4he3SxbXHjbEBk[W6lZYKgZ4VtdCCuaX7lJEhOU052NTmsJGlEPTB;ODDuUS=> NF7SN2I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUOzOFU3QSd-MUGzN|Q2Pjl:L3G+
human ovarian cancer cell line (SK-OV-3) M2qxb2N6fG:2b4jpZ:Kh[XO|YYm= MX3JckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDveoFzcWGwIHPhcoNmeiClZXzsJIxqdmViKGPLMW9XNTNrLDDJR|UxRTFzIH7N M2rZR|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
human colon cancer cell line (WiDr) M{jQeWN6fG:2b4jpZ:Kh[XO|YYm= MXHJckBXcXS{bzDjfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDjc4xwdiClYX7j[ZIh[2WubDDsbY5mKCiZaVTyLUwhUUN3ME2xOEBvVQ>? MnPYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTF|M{S1OlkoRjFzM{O0OVY6RC:jPh?=
human lung cancer cell line (A549) NIrPT2hEgXSxdH;4bYPDqGG|c3H5 NGjHNoJKdiCYaYTyc{BkgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBtfW6pIHPhcoNmeiClZXzsJIxqdmViKFG1OFkq M3f0[|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFzM{O0OVY6Lz5zMUOzOFU3QTxxYU6=
NSCLC-H460 NFzTRnhEgXSxdH;4bYPDqGG|c3H5 NYDSZYlqS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hdm:wLYPtZYxtNWOnbHygcJVv\yClYYLjbY5wdWFiY3XscEBtcW6nIFi0OlAhME6VQ1zDMWg1PjBrLDDJR|UxRThyIH7N NUG2[ZBuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG1OlM6OjVpPkGxOVY{QTJ3PD;hQi=>
PC-3 carcinoma cell line NWDQV3NVT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MWrDc45k\W62cnH0bY9vKHKncYXpdoVlKHSxIHnubIljcXRiZ4Lve5RpKG:oIHj1cYFvKHC{b4P0ZZRmKFCFLUOgZ4Fz[2mwb33hJINmdGxibHnu[UwhUUN3ME2zOU43KG6P MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTR3NEKzNEc,OTV2NUSyN|A9N2F-
human HCT116 colon cancer cell line MWHGeY5kfGmxbjDhd5NigQ>? M1iyNWlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IHj1cYFvKEiFVEGxOkBkd2yxbjDjZY5k\XJiY3XscEBtcW6nLDDJR|UxRTdibl2= NIDwWVY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUiwPFQ2Pid-MUW4NFg1PTZ:L3G+
human Bel-7402 liver cancer cell line NGnYcXdHfW6ldHnvckBie3OjeR?= NHi4ZmdKdmirYnn0c5J6KGOxbnPlcpRz[XSrb36gZYdicW6|dDDoeY1idiCEZXytO|QxOiCuaY\ldkBk[W6lZYKgZ4VtdCCuaX7lMEBKSzVyPUOuNVkh|ryP Mn;HQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV6MEi0OVYoRjF3OEC4OFU3RC:jPh?=
human tumor HL60 cell-line MX7GeY5kfGmxbjDhd5NigQ>? MonDN{Bl[Xm| MkfuTY4ufmm2cn:gbY5pcWKrdH;yfUBkd26lZX70doF1cW:wIH\vdkBpfW2jbjD0eY1weiCKTE[wJINmdGxvbHnu[UB4[XNiZHX0[ZJucW6nZDD1d4lv\yCVUlKgZZN{[XliYX\0[ZIhOyCmYYnzJI9nKGmwY4XiZZRqd25uIFnDOVA:OTlibl2= M3m4b|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3OUGzPVk3Lz5zNUmxN|k6PjxxYU6=
human H460 cell M1zpR2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEXmeHlKdmirYnn0bY9vKG:oIHj1cYFvKEh2NkCgZ4VtdCCpcn;3eIgtKEmFNUC9PFAhdk1? MoLQQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTZ7MUO3NFYoRjF4OUGzO|A3RC:jPh?=
MDA-MB-435 NHywOYZHfW6ldHnvckBie3OjeR?= M2[ycmlvcGmkaYTpc44h[WejaX7zeEBOTEFvTVKtOFM2KFNiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyCrbjD0bIUh[WK|ZX7j[UBw\iCjbHL1cYlvNCCLQ{WwJF0hOC5yMEWg{txONg>? NVv0WYJWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUGwOVI5ODJpPkGxNFUzQDB{PD;hQi=>
MDA-MB-435 MYDGeY5kfGmxbjDhd5NigQ>? M4\RZmlvcGmkaYTpc44h[WejaX7zeEBOTEFvTVKtOFM2KFNiaIXtZY4h[nKnYYP0JINidmOncjDj[YxteyCrbjD0bIUheHKnc3XuZ4Uhd2ZiM{CgcYcwdUxiSGPBMEBKSzVyIE2gNE4xPSEQvF2u NGK5[2g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMUC1NlgxOid-MUGwOVI5ODJ:L3G+
PC-6/SN2-5H NVT1U4R7TnWwY4Tpc44h[XO|YYm= NHXqUJVVWF:WUlHOV3BQWlSHUkqgeZB1[WunIHnuJI1mdWK{YX7lJJZme2mlbHWg[pJwdSCSQz22M3NPOi13SDDj[YxteyxiS32gQUA1KM7:TT6= NFLlfmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMU[4PFk5Oid-MUG2PFg6QDJ:L3G+
HT-29 NIrrcGVHfW6ldHnvckBie3OjeR?= MnKwTY4hfmm2cn:gbY5pcWKrdH;yfUBkd26lZX70doF1cW:wIILldZVqemWmIHHnZYlve3RiSGStNlkhcHWvYX6gZ49td25iY3HuZ4VzKGOnbHzzMEBKSzVyIE2gNE4xOjd|IN88UU4> MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOjZzN{myO{c,OTJ4MUe5Nlc9N2F-
SaoS2 M4m3XGZ2dmO2aX;uJIF{e2G7 MWnUVH9VWkGQU2DPVnRGWjpiZIL1[{Bz\XOrc4ThcoNmMEmvYYTpcoljKG2nc4nsZZRmMSCrbjDCR3JRNWW6cILld5NqdmdiU3HvV|Ih[2WubIOsJGlEPTBiPTCwMlE4PiEQvF2u MoHaQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTVyNUm4PFEoRjF3MEW5PFgyRC:jPh?=
DU145 MoPGRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MVO5OkBpenN? M2G5XWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iRGWxOFUh[2WubIOgZYZ1\XJiOU[gbJJ{NCCLQ{WwJF0hOC5yMESg{txONg>? NH3ZXFI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK3OlE1OSd-MUiyO|YyPDF:L3G+
MIA PaCa MXrBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? M1vQO|k3KGi{cx?= M1PY[WFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVnBJHBiS2FiY3XscJMh[W[2ZYKgPVYhcHK|LDDJR|UxKD1iMD6wNFYh|ryPLh?= NWTFNWExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUiyO|YyPDFpPkG4Nlc3OTRzPD;hQi=>
HT29 MXjBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MUe5OkBpenN? MUTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWMkmgZ4VtdHNiYX\0[ZIhQTZiaILzMEBKSzVyIE2gNE4xOTJizszNMi=> NIHGOFk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEK3OlE1OSd-MUiyO|YyPDF:L3G+
H460 NVPGSGFZSW62aYDyc4xq\mW{YYTpeoUh[XO|YYm= NV7EbIpSOSCqch?= M2WzWWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSES2NEBk\WyuczDh[pRmeiBzIHjyJI9nKGS{dXeg[Zhxd3O3cnWgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC5{MjFOwG0v MmrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh2MkSxN|MoRjF6NEK0NVM{RC:jPh?=
HT29 MXTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NYjYSWl{OSCqch?= M4mxN2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSGSyPUBk\WyuczDh[pRmeiBzIHjyJI9nKGS{dXeg[Zhxd3O3cnWgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOC54NzFOwG0v NWj5OG8zRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NlQyOzNpPkG4OFI1OTN|PD;hQi=>
HT29 MmmxRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? Mn\LNUBpeg>? NVTWXmhwSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBDS1KSIH;2[ZJmgHC{ZYPzbY5oKG2rdH;4ZY51em:wZT3y[ZNqe3SjboSgbJVu[W5iSGSyPUBk\WyuczDh[pRmeiBzIHjyJI9nKGS{dXeg[Zhxd3O3cnWgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{NCCLQ{WwJF0hOTFwNTFOwG0v NWXl[JA4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0NlQyOzNpPkG4OFI1OTN|PD;hQi=>
H460 NUjPfHVqS3m2b4TvfIlkcXS7IHHzd4F6 NVi2[IxUS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUDR4MDDj[YxteyxiSVO1NEA:KDBwMkKg{txONg>? NUPUT3VVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi0N|QyPTNpPkG4OFM1OTV|PD;hQi=>
A549 NHPuRlNEgXSxdH;4bYNqfHliYYPzZZk> MnSzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{BjgSCVUlKgcYV1cG:mLDDJR|UxKD1iMD6wPEDPxE1w M2f2N|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OUi2PFA4Lz5zOEm4OlgxPzxxYU6=
HT-29 MkXWR5l1d3SxeHnjbZR6KGG|c3H5 MX3DfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BjgSCVUlKgcYV1cG:mLDDJR|UxKD1iMD6xNkDPxE1w NYPmU5h3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi5PFY5ODdpPkG4PVg3QDB5PD;hQi=>
PC6 MWXBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MoTROkBl[Xm| M4fwfWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iUFO2JINmdGy|IHPhdpJ6cW6pIIDSR{Bi\nSncjC2JIRigXNuIFnDOVAhRSByLkCwNFQ{KM7:TT6= MWm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ3NEi0N{c,OTl{NUS4OFM9N2F-
HCT116 M{f1cWFvfGmycn;sbYZmemG2aY\lJIF{e2G7 MWWzJIRigXN? MUjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiFVEGxOkBk\WyuczDh[pRmeiB|IHThfZMtKEmFNUCgQUAxNjByMEW1JO69VS5? NWPSZXdHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyOVQ5PDNpPkG5NlU1QDR|PD;hQi=>
QG56 NGXQfoJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MXuzJIRigXN? MVzBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKFGJNU[gZ4VtdHNiYX\0[ZIhOyCmYYnzMEBKSzVyIE2gNE4xODJ6IN88UU4> M3izUFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW0PFQ{Lz5zOUK1OFg1OzxxYU6=
NCI-H460 MX7BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? MmGyN{Bl[Xm| NGHldnFCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF7DTU1JPDZyIHPlcIx{KGGodHXyJFMh\GG7czygTWM2OCB;IECuNFA{OyEQvF2u NFjSSYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUK1OFg1Oyd-MUmyOVQ5PDN:L3G+
BCRP MmrWRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl? MlXTOkBl[Xm| NWTTUWhRSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR|Yh\XiycnXzd4lv\yCEQ2LQJINmdGy|IHHmeIVzKDZiZHH5d{whUUN3MDC9JFAvODB3MTFOwG0v MoX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{NUS4OFMoRjF7MkW0PFQ{RC:jPh?=
KB3-1 MUPDfZRwfG:6aXPpeJkh[XO|YYm= NFH3Nmk1KGSjeYO= MWTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDLRlMuOSClZXzsd{Bi\nSncjC0JIRigXNiYomgUXRVKG2ndHjv[EwhUUN3MDC9JFAvODB2IN88UU4> NHn4[oE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUOwN|MxPid-MUmzNFM{ODZ:L3G+
KBV1 NYrweWRNS3m2b4TvfIlkcXS7IHHzd4F6 NUOyNGNJPCCmYYnz MWnDfZRwfG:6aXPpeJkh[WejaX7zeEBOTFJzIH;2[ZJmgHC{ZYPzbY5oKGi3bXHuJGtDXjFiY3XscJMh[W[2ZYKgOEBl[Xm|IHL5JG1VXCCvZYToc4QtKEmFNUCgQUAxNjB2NjFOwG0v MUe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTNyM{OwOkc,OTl|MEOzNFY9N2F-
KBH5.0 MlnxR5l1d3SxeHnjbZR6KGG|c3H5 MWO0JIRigXN? NHXEN45EgXSxdH;4bYNqfHliYXfhbY5{fCCEQ2LQJI93\XKneIDy[ZN{cW6pIHj1cYFvKEuESEWuNEBk\WyuczDh[pRmeiB2IHThfZMh[nliTWTUJI1mfGixZDygTWM2OCB;IECuN{DPxE1w NUGxTGNbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNFM{ODZpPkG5N|A{OzB4PD;hQi=>
NCI-H460 NH\5bY5CdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MX2xJIhz MYrBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE6FST3IOFYxKGOnbHzzJIFnfGW{IIPoc5J1KHSncn2g[Zhxd3O3cnWg[o9zKDFiaIKgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGmwIHTyeYcu\nKnZTDt[YRqfW1uIFnDOVAhRSByLkGzJO69VS5? MljoQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3M{C3NlAoRjF7NUOwO|IxRC:jPh?=
A549/ATCC M3;MVGFvfGm2dX3vdkBie3OjeR?= NHTWWHVCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6N0GWQ1OgZ4VtdHNiYomgV3JDKG2ndHjv[EwhUUN3MDC9JFAvODh6IN88UU4> MlvjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3NEG0PFMoRjF7NUSxOFg{RC:jPh?=
HT-29 MnrDRY51cXS3bX;yJIF{e2G7 NHTUdVJCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{BjgSCVUlKgcYV1cG:mLDDJR|UxKD1iMD6xO{DPxE1w MnfOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3NEG0PFMoRjF7NUSxOFg{RC:jPh?=
gastric cancer cells MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWDtcmZYPzJiaILz MmjpS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6g[4F{fHKrYzDjZY5k\XJiY3XscJMh[W[2ZYKgO|IhcHK|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFfJOVAhRSByLkC2OkDPxE1w NFnqXHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEi4OFA5QSd-MkC4PFQxQDl:L3G+
lung cancer cells M{PieGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M13nbVczKGi{cx?= MlvQS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gcJVv\yClYX7j[ZIh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IIP1cIZwemixZHHtbY5mKEJiYYPzZZktKEeLNUCgQUAxNjB4NjFOwG0v M1TwTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEi0NFg6Lz5{MEi4OFA5QTxxYU6=
colon cancer cells Mon0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFG0R2s4OiCqcoO= NYnWdYJPT3Kxd4ToJIlvcGmkaYTpc44hd2ZiaIXtZY4h[2:ub36gZ4Fv[2W{IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDHTVUxKD1iMD6wOlYh|ryPLh?= MkjIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB6OESwPFkoRjJyOEi0NFg6RC:jPh?=
HT-29 NGH3NmREgXSxdH;4bYNqfHliYYPzZZk> MXHDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{whUUN3MDC9JFAvODB3OTFOwG0v MnnFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF2N{C4OlQoRjJzNEewPFY1RC:jPh?=
A549 MonsR5l1d3SxeHnjbZR6KGG|c3H5 NETFUpVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCPTR7IHPlcIx{NCCLQ{WwJF0hOC5yNEeg{txONg>? NUS1fmxpRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG0O|A5PjRpPkKxOFcxQDZ2PD;hQi=>
PC3 NFL3WnBEgXSxdH;4bYNqfHliYYPzZZk> MlWwO|IhcHK| MULDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDQR|Mh[2WubIOg[ZhxemW|c3nu[{BidHCqYUXi[ZRiOyCrboTl[5JqdiCjc4Pld5Nm\CCjczDj[YxtKHO3co\peoFtKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjByMk[g{txONg>? NEXIN|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{Mkm1PVI1Pid-MkK5OVkzPDZ:L3G+
A2780 M3jGPWN6fG:2b4jpZ4l1gSCjc4PhfS=> NIn1eoE4OiCqcoO= NIjJSY1EgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBCOjd6MDDj[YxteyCxdnXy[ZhxemW|c3nu[{BidHCqYUXi[ZRiOyCrboTl[5JqdiCjc4Pld5Nm\CCjczDj[YxtKHO3co\peoFtKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjByOTFOwG0v MmjDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7NUmyOFYoRjJ{OUW5NlQ3RC:jPh?=
DU145 MmfrR5l1d3SxeHnjbZR6KGG|c3H5 MWjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDEWVE1PSClZXzsd{whUUN3MDC9JFAvODNizszNMi=> MonkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3N{i1OFUoRjJ|NUe4OVQ2RC:jPh?=
HT-29 M4riRmN6fG:2b4jpZ4l1gSCjc4PhfS=> NIXXZ5VEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyxiSVO1NEA:KDBwMEOg{txONg>? MnjxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3N{i1OFUoRjJ|NUe4OVQ2RC:jPh?=
L1210 NVfmTopwS3m2b4TvfIlkcXS7IHHzd4F6 NUHrSXBYS3m2b4TvfIlkcXS7IHHnZYlve3RibX;1d4UhVDF{MUCgZ4VtdHNuIFnDOVAhRSByLkC0JO69VS5? Ml61QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3N{i1OFUoRjJ|NUe4OVQ2RC:jPh?=
DU145 M4jvfGN6fG:2b4jpZ4l1gSCjc4PhfS=> M2faPFczKGi{cx?= NU\xUIl1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iClZXzsJJZq[WKrbHn0fUBi\nSncjC3NkBpenNiYomgUXRUKGG|c3H5MEBKSzVyIE2gNE4yOSEQvF2u MkX0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MkK5PFEoRjJ|NkKyPVgyRC:jPh?=
DU145 M{\V[2Z2dmO2aX;uJIF{e2G7 NGrnR5IxNjFidH:gNE42KHWP MmrwNlQhcHK| MoiwTY5pcWKrdHnvckBw\iCKRFHDJIlvKGi3bXHuJGRWOTR3IHPlcIx{KGG|c3Xzd4VlKGG|IIXwdoVofWyjdHnvckBw\iCyMkH3ZYYyKGW6cILld5Nqd25iYYSgNE4yKHSxIECuOUB2VSCjZoTldkAzPCCqcoOgZpkhX2W|dHXyckBjdG:2IHHuZYx6e2m| NVfCdFBPRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NlI6QDFpPkKzOlIzQThzPD;hQi=>
A549 MoLPR5l1d3SxeHnjbZR6KGG|c3H5 NGS0SnU{KGSjeYO= MlLuR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gRVU1QSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA{KGSjeYOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5yMEK3NkDPxE1w MleyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mkm4O|AoRjJ2NUK5PFcxRC:jPh?=
HCT116 MoS1R5l1d3SxeHnjbZR6KGG|c3H5 MYCzJIRigXN? MnjYR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDNiZHH5d{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkCzNUDPxE1w Mlj2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mkm4O|AoRjJ2NUK5PFcxRC:jPh?=
HT-29 NEfXdm1EgXSxdH;4bYNqfHliYYPzZZk> M13J[FMh\GG7cx?= MXLDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA{KGSjeYOgZpkhW1KEIHHzd4F6NCCLQ{WwJF0hOC5zME[2O{DPxE1w NELUWIs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyPVg4OCd-MkS1Nlk5PzB:L3G+
HCT116 NITndW9EgXSxdH;4bYNqfHliYYPzZZk> M4LSfGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhEXDFzNjDj[YxteyxiSVO1NEA:KDBwMU[2JO69VS5? NV34e5VURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1Nlk5PzBpPkK0OVI6QDdyPD;hQi=>
MDA-MB-231 M2LobWN6fG:2b4jpZ4l1gSCjc4PhfS=> MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvMkOxJINmdGy|LDDJR|UxKD1iMD6xO|Yh|ryPLh?= M4\iTFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUK5PFcxLz5{NEWyPVg4ODxxYU6=
A549 NHe5TlJEgXSxdH;4bYNqfHliYYPzZZk> M{nkTGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMtKEmFNUCgQUAxNjJ3OTFOwG0v Ml7GQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3Mkm4O|AoRjJ2NUK5PFcxRC:jPh?=
HEK293 M1LG[2N6fG:2b4jpZ4l1gSCjc4PhfS=> MoDBO|IhcHK| NW\jb29JUW62cnnud4lkKGO7dH;0c5hq[2m2eTDh[4FqdnO2IFjFT|I6OyClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25iaX6gZ4VtdCC4aXHibYxqfHliYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVe1NEA:KDBwMEC1JO69VS5? NVvvT4hGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyO|IxPTVpPkK1NlczODV3PD;hQi=>
HCT116 M{HjV2N6fG:2b4jpZ4l1gSCjc4PhfS=> MoPEO|IhcHK| MkHrR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFczKGi{czDifUB{fWyob4Loc4RidWmwZTDCJIF{e2G7LDDJR|UxKD1iMD6wNFQzQCEQvF2u MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTh|NUO1PUc,OjV6M{WzOVk9N2F-
HT-29 MmfDR5l1d3SxeHnjbZR6KGG|c3H5 MYC3NkBpenN? NH3qVWVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OCB;IECuNFE5PTRizszNMi=> M2Ljb|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OEO1N|U6Lz5{NUizOVM2QTxxYU6=
HCT15 MYDDfZRwfG:6aXPpeJkh[XO|YYm= MWm3NkBpenN? NWnkPYp2S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEOWMUWgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIHnubIljcXSrb36gZYZ1\XJiN{KgbJJ{KGK7IGPSRkBie3OjeTygTWM2OCB;IECuNFA5KM7:TT6= MoLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlAoRjJ5ME[wO|YxRC:jPh?=
U251 NH7uNYNEgXSxdH;4bYNqfHliYYPzZZk> MX63NkBpenN? NFfJO2JEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBWOjVzIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkCyNUDPxE1w NHm4OG09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3OCd-MkewOlA4PjB:L3G+
U87MG NFzrOppEgXSxdH;4bYNqfHliYYPzZZk> MWS3NkBpenN? M17iNWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJHU5P02JIHPlcIx{KGG|c3Xzd4VlKGG|IHfyc5d1cCCrbnjpZol1cW:wIHHmeIVzKDd{IHjyd{BjgSCVUlKgZZN{[XluIFnDOVAhRSByLkCzJO69VS5? MUW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4MEe2NEc,OjdyNkC3OlA9N2F-
HT-29 MmXwR5l1d3SxeHnjbZR6KGG|c3H5 M4juWlczKGi{cx?= MmriR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gTHQuOjliY3XscJMh[XO|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYX\0[ZIhPzJiaILzJIJ6KFOUQjDhd5NigSxiSVO1NEA:KDBwMEW0JO69VS5? NGjnOo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{C2NFc3OCd-MkewOlA4PjB:L3G+
MCF7 NU\STnlSS3m2b4TvfIlkcXS7IHHzd4F6 M3vzXFczKGi{cx?= MVTDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAxNjVzNTFOwG0v MmPZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjdyNkC3OlAoRjJ5ME[wO|YxRC:jPh?=
MDA-MB-231 NI\tPVhEgXSxdH;4bYNqfHliYYPzZZk> NV\kVmo6PzJiaILz NFfHRVhEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBOTEFvTVKtNlMyKGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFczKGi{czDifUBUWkJiYYPzZZktKEmFNUCgQUAyNjl5IN88UU4> MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzB4MEe2NEc,OjdyNkC3OlA9N2F-
NCI-H460 NFz5UWVEgXSxdH;4bYNqfHliYYPzZZk> M4PQelI1KGi{cx?= MmjNR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNicILleJJm[XSnZDDmc5IhOjRiaILzJJVv\GW{IH7vdo1wgGmlIHPvcoRqfGmxbjDmc4xtd3enZDDifUBkd22yb4Xu[EB4[XOqb4X0JI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO|YYmsJGlEPTBiPTCwMlA2KM7:TT6= MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MEm5O{c,Ojh|NUC5PVc9N2F-
NCI-H460 M3HBcWN6fG:2b4jpZ4l1gSCjc4PhfS=> MYeyOEBpenN? MYfDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCycnX0doVifGWmIH\vdkAzPCCqcoOgeY5l\XJiaInwc5hq[yClb37kbZRqd25iZn;scI94\WRiYomgZ49ueG:3bnSge4F{cG:3dDDt[YF{fXKnZDDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR|UxKD1iMD6wOkDPxE1w MYe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDN3MEm5O{c,Ojh|NUC5PVc9N2F-
HT-29 NWf0V4VxS3m2b4TvfIlkcXS7IHHzd4F6 NEjaeokzPCCqcoO= NEf2[ZNEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCycnX0doVifGWmIH\vdkAzPCCqcoOgeY5l\XJibn;ycY95cWNiY3;u[Il1cW:wIH\vcIxwf2WmIHL5JINwdXCxdX7kJJdie2ixdYSgcYVie3W{ZXSgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEKuO|Qh|ryPLh?= MnXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjh|NUC5PVcoRjJ6M{WwPVk4RC:jPh?=
HT-29 M2jC[mN6fG:2b4jpZ4l1gSCjc4PhfS=> M1TuRVI1KGi{cx?= M{S5Z2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KHC{ZYTy[YF1\WRiZn;yJFI1KGi{czD1coRmeiCqeYDvfIlkKGOxbnTpeIlwdiCob3zsc5dm\CCkeTDjc41xd3WwZDD3ZZNpd3W2IH3lZZN2emWmIHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB|LkexJO69VS5? NH;1TYU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OEO1NFk6Pyd-MkizOVA6QTd:L3G+
NCI-H460 MoP5R5l1d3SxeHnjbZR6KGG|c3H5 MoTDO|IhcHK| MUDDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDOR2kuUDR4MDDj[YxteyCjc4Pld5Nm\CCjczDndo94fGhicnXkeYN1cW:wIIXu[IVzKGi7cH;4bYMh[2:wZHn0bY9vKGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjB2NzFOwG0v MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd2ME[xN{c,Ojh5NEC2NVM9N2F-
NCI-H460 NYjCPINGS3m2b4TvfIlkcXS7IHHzd4F6 MoLDO|IhcHK| MnTnR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gUmNKNUh2NkCgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIILl[JVkfGmxbjD1coRmeiCwb4Ltc5hq[yClb37kbZRqd25iYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwMEWg{txONg>? MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd2ME[xN{c,Ojh5NEC2NVM9N2F-
HT-29 MoHjR5l1d3SxeHnjbZR6KGG|c3H5 M3\TS|czKGi{cx?= MVPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghemWmdXP0bY9vKHWwZHXyJI5wem2xeHnjJINwdmSrdHnvckBi\nSncjC3NkBpenNiYomgUXRVKGG|c3H5MEBKSzVyIE2gNE4xQTZizszNMi=> M4TpXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6N{SwOlE{Lz5{OEe0NFYyOzxxYU6=
HT-29 NYf0THViS3m2b4TvfIlkcXS7IHHzd4F6 NGG2VYc4OiCqcoO= NYnneGE4S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUFRvMkmgZ4VtdHNiYYPz[ZN{\WRiYYOg[5Jwf3SqIILl[JVkfGmxbjD1coRmeiCqeYDvfIlkKGOxbnTpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC5zMUmg{txONg>? MVy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQDd2ME[xN{c,Ojh5NEC2NVM9N2F-
TC32 M2LOeJFJXFNiYYPzZZk> MYfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhXEN|MjDj[Yxtew>? M3;JbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 MmXLdWhVWyCjc4PhfS=> NFjLeGJyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQU[3N{Bk\Wyucx?= NXvqUFB3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
DAOY Mk\TdWhVWyCjc4PhfS=> MUDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>? MkfKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Saos-2 NFnsVFVyUFSVIHHzd4F6 NUPHUZQ{eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=> NVTacox1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-37 Mkm4dWhVWyCjc4PhfS=> MnfTdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy| MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
RD M2T5Z5FJXFNiYYPzZZk> M3;4VJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCURDDj[Yxtew>? MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
SK-N-SH NX\1XpM5eUiWUzDhd5NigQ>? M37iPJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMXNJKGOnbHzz MmDLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
BT-12 NGntUnhyUFSVIHHzd4F6 M3r6W5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?= M2Xp[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R) MofVdWhVWyCjc4PhfS=> NX3qXJB4eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz NFK2[G89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB1643 M2fmfZFJXFNiYYPzZZk> NXfGblB7eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IF7CNVY1OyClZXzsdy=> MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
OHS-50 MlLTdWhVWyCjc4PhfS=> MWDxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhV0iVLUWwJINmdGy| NUHDe|NoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12 MlXkdWhVWyCjc4PhfS=> MkGwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRnQuOTJiY3XscJM> MUC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh41 NXTr[XFZeUiWUzDhd5NigQ>? MkSydWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN? NE\FUm09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
NB-EBc1 M2LkVJFJXFNiYYPzZZk> NIHZUplyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBPSi2HQnOxJINmdGy| NUjveXVLRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
SK-N-SH M3nEUZFJXFNiYYPzZZk> M{e4R5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHNMNU5vU1igZ4VtdHN? MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 Mn7OdWhVWyCjc4PhfS=> NXfrbFRDeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC|Y4Ll[Y4h\m:{IGLoN|Ah[2WubIO= M4P4R|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
A673 NXHLVZc6eUiWUzDhd5NigQ>? NVTWOGUxeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSTZ5MzDj[Yxteyl? MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
Rh30 MYDxTHRUKGG|c3H5 Mmi4dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog{OCClZXzsdy=> MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR|NUGzPUc,Ojl2M{WxN|k9N2F-
U-2 OS NVPZUVRkeUiWUzDhd5NigQ>? MXXxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDVMVIhV1NiY3XscJM> Mnq4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
Rh41 MYTxTHRUKGG|c3H5 M{LycZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpPDFiY3XscJM> Mn74QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2 MWTxTHRUKGG|c3H5 Mn3GdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO= M1P0bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC NWXEWndReUiWUzDhd5NigQ>? MVTxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW|IH\vdkBlenWpIILldJVzeG:|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhW0tvTj3NR{Bk\Wyucx?= NX7PWlk3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB-EBc1 Mmm2dWhVWyCjc4PhfS=> NEfMcWxyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=> M1jjfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
LAN-5 MWTxTHRUKGG|c3H5 NIrVWoFyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTFHOMVUh[2WubIO= NGPWcII9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
Rh18 MXHxTHRUKGG|c3H5 MnnZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqMUigZ4VtdHN? NF74Z|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N|UyOzl:L3G+
HCT116 NFe3dZFCdnSrcILvcIln\XKjdHn2[UBie3OjeR?= MUG3NkBpenN? M3XpOmFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSFPUNVE3KGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDTVmIh[XO|YYmsJGlEPTBiPTCwMlAxODd6IN88UU4> NGP2SnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9|MEGxOVQ6Oid-M{CxNVU1QTJ:L3G+
A549 MUTBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>? NHfLOmg4OiCqcoO= M{L4TWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB5MjDodpMh[nliU2LCJIF{e2G7LDDJR|UxKD1iMD6wNFE3OiEQvF2u MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODFzNUS5Nkc,OzBzMUW0PVI9N2F-
MCF7 NF\LXFhEgXSxdH;4bYNqfHliYYPzZZk> NHy5W4k4OiCqcoO= NWq0OYY{S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVUOINzDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OCB;IECuNFAxOSEQvF2u MlvrQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzNkmwN|goRjNyMU[5NFM5RC:jPh?=
A549 MoH5R5l1d3SxeHnjbZR6KGG|c3H5 MVm3NkBpenN? NWDKNIJKS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hSTV2OTDj[YxteyCjZoTldkA4OiCqcoOgZpkhe3WuZn;ybI9l[W2rbnWgRkBie3OjeTygTWM2OCB;IECuNkDPxE1w MnS1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzBzNkmwN|goRjNyMU[5NFM5RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-Chk1 / Chk1 / Topo I ; 

PubMed: 18509065     


Log-phase Ovcar-5 cells were treated for 24 h with diluent (0.1% DMSO, lanes 1 and 6), gemcitabine at 12.5, 25, 50 or 100 nM (lanes 2-5, respectively), or SN-38 at 2.5, 5, 10, 20 and 40 nM in the absence (lanes 7-11) or presence (lanes 12-17) of 50 nM gemcitabine. At the end of the incubation, whole cell lysates were prepared, subjected to SDS-PAGE, transferred to nitrocellulose, and probed with reagents that recognize phospho-Ser345-Chk1, total Chk1, topo I or, as control, β-actin. Because of the limited number of lanes on our electrophoresis apparatus, lanes 1-5 and 6-17 represent two different membranes from the same experiment that were probed simultaneously.

18509065
Growth inhibition assay
Cell viability; 

PubMed: 25759163     


(A) Drug sensitivity towards SN‐38 and oxaliplatin for the parental and drug resistant cell lines. Cells were exposed to a range of drug concentrations for 48 h and cell viability was assessed by an endpoint MTT assay. Results of representative experiments are shown. Green (triangle) is the parental cell line, blue (diamond) the SN‐38 resistant cell line, and red (square) the oxaliplatin resistant cell line.

25759163
体内研究 口服给药后,SN-38的最高浓度出现在1小时后,并且未结合的SN-38内酯在小鼠血浆在1000纳克/毫升时百分比是3.4 +/- 0.67%,而在100纳克/毫升的未结合的百分比是1.18 +/- 0.14%。在含人类神经母细胞瘤的裸鼠中SN-38内酯的AUC大于在非肿瘤息动物的量。

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
- 合并

拓扑异构酶I检测:

一个单位(本研究的条件下,使0.5微克SV40 DNA完全松弛的最小量)拓扑异构酶I, 0.5微升的测试化合物,和0.5μg SV40的DNA按顺序加入反应缓冲液中,它是由25毫摩尔Tris -盐酸(pH值7.5),50 mM的KCl, 5 mM的氯化镁,0.25毫摩尔EDTA二钠盐,0.25 mM二硫苏糖醇,15 μg/毫升牛血清白蛋白和5 %的甘油。然后,将反应混合物(50 μL)在37 ℃温育10分钟,并将该反应通过7.5 μL 溶液在37 ℃温育30分钟终止, 1%十二烷基硫酸钠, 20 mM的EDTA二钠盐,和0.5 mg/mL 蛋白酶K。 样品和5 μL 的上样缓冲液混合,上样缓冲液包含10 mM磷酸氢二钠,31.3%蔗糖,0.3%溴酚蓝。松弛(Ir形式)的DNA从超螺旋(形式I)中分离,带切口的( II型)的DNA通过电泳在0.8%琼脂糖凝胶分离,电泳是在在2 μg/mL chloroquine, 10 mM EDTA, 30 mM 磷酸氢二钠存在下在50毫安和20 V条件下进行17小时。电泳后,将凝胶用0.05%溴化乙锭染色并用UV光(302纳米)拍摄。 DNA量是用密度计进行定量。
细胞实验:[3]
- 合并
  • Cell lines: A-172, U-87和LA-567
  • Concentrations: 0 -1000 nM
  • Incubation Time: 48 小时
  • Method: MTT 检测
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 21 mg/mL (53.51 mM)
Water Insoluble
Ethanol Insoluble

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 392.4
化学式

C22H20N2O5

CAS号 86639-52-3
储存条件 粉状
溶于溶剂
别名 NK012

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、SDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT05101096 Recruiting Drug: Sacituzumab Govitecan-hziy Advanced Solid Tumors or Triple-negative Breast Cancer Gilead Sciences October 20 2021 Phase 1|Phase 2
NCT04866641 Recruiting Drug: T-1201 Injection 100 mg Kit Advanced Solid Tumor Taivex Therapeutics Corporation June 24 2021 Phase 1
NCT04617522 Recruiting Drug: Sacituzumab Govitecan-hziy Advanced or Metastatic Solid Tumor|Liver Failure Gilead Sciences April 6 2021 Phase 1
NCT03995706 Recruiting Drug: Sacituzumab Govitecan Glioblastoma The University of Texas Health Science Center at San Antonio|Gilead Sciences July 17 2019 Early Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项
免费分装抑制剂
Tags: 购买SN-38 | SN-38供应商 | 采购SN-38 | SN-38价格 | SN-38生产 | 订购SN-38 | SN-38代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID